Table 1.
Clinical and demographic characterization of MOG-IgG patients.
| Age (years) | 1–10 | 11–20 | 21–30 | 31–40 | 41–50 | >50 | Total cohort | |
|---|---|---|---|---|---|---|---|---|
| F/M | 6/7 | 3/9 | 4/3 | 7/8 | 1/2 | 2/0 | 23/29 | |
| ON | 8/12 (67%) | 9/11 (82%) | 2/5(40%) | 9/14 (64%) | 2/2 (100%) | 2/3 (67%) | 32/46 (69.5%) | |
| Myelitis | 4/12 (33%) | 3/11 (27%) | 3/5 (60%) | 7/14 (50%) | 2/2 (100%) | 1/3 (33%) | 19/46 (41%) | |
| ON and Myelitis | 1/12 (8%) | 1/11 (9%) | 2/14 (14%) | 2/2 (100%) | 6/46 (13%) | |||
| MRI Brain | Normal | 5/12 (42%) | 7/11 (64%) | 3/5 (60%) | 10/14 (71%) | 1/2 (50%) | 29/46 (63%) | |
| ADEM | 4/12 (33%) | 3/11 (27%) | 1/5 (20%) | 1/14 (7%) | 3/3(100%) | 8/46(17%) | ||
| NMOSD like (36) | 1/12 (8%) | 1/5 (20%) | 2/14 (14%) | 3/46 (6.5%) | ||||
| MS like | 1/11 (9%) | 1/2 (50%) | 2/46 (4%) | |||||
| Disease course | Relapsing | 3/12(25%) | 5/11 (45%) | 1/5 (20%) | 9/14 (64%) | 2/2(100%) | 20/46(43%) | |
| Monophasic | 8/12 (67%) | 6/11 (54%) | 4/5 (80%) | 5/14 (36%) | 3/3(100%) | 26/46 (56%) | ||
| OCB | 1/11 (8%) | 1/11(9%) | 1/5 (20%) | 2/14 (14%) | 1/3 (33%) | 6/46 (13%) | ||
| Diagnosis | ON | 6/12 (50%) | 6/11 (54%) | 2/5 (40%) | 5/14 (36%) | 2/3 (67%) | 21/46 (46%) | |
| ADEM | 6/12 (50%) | 3/11 (27%) | 9/46 (19.5%) | |||||
| Myelitis | 2/11 (18%) | 2/5 (40%) | 4/14 (29%) | 1/3 (33%) | 9/46 (19.5%) | |||
| NMOSD like | 1/5 (20%) | 3/14 (21%) | 1/2 (50%) | 5/46 (11%) | ||||
| MS like | 2/14 (2%) | 1/2 (50%) | 3/46 (6.5%) | |||||
| MOG-abs seropositive | 13/49(26%) | 12/97 (12%) | 7/136 (5%) | 15/90 (17%) | 3/98 (3%) | 3/107 (3%) | 53/683 (7.8%) |